Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
Identifieur interne : 001268 ( Main/Exploration ); précédent : 001267; suivant : 001269Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
Auteurs : Galia Zacay [Israël] ; Yair Levy [Israël]Source :
- Best practice & research. Clinical rheumatology [ 1532-1770 ] ; 2018.
Descripteurs français
- KwdFr :
- MESH :
- anatomopathologie : Sclérodermie systémique.
- pharmacologie : Anticorps monoclonaux humanisés.
- traitement médicamenteux : Sclérodermie systémique.
- usage thérapeutique : Anticorps monoclonaux humanisés.
- Adulte d'âge moyen, Femelle, Humains, Mâle, Résultat thérapeutique.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Antibodies, Monoclonal, Humanized.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- drug therapy : Scleroderma, Systemic.
- pathology : Scleroderma, Systemic.
- Female, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
The treatment of systemic sclerosis (SSc) presents a clinical challenge because of the progressive nature of the disease, relatively poor prognosis, and lack of a proven treatment. In the last 10 years, several studies demonstrated the importance of interleukin 6 (IL6) as a pivotal cytokine in the development of fibrosis and angiopathy, especially in SSc. Tocilizumab, an IL6 receptor antibody, has shown promising results for patients with SSc. A total of 16 patients with SSc were treated with tocilizumab; 14 were female and 2 were male, with a median age of 45.5 years and median disease duration of 31.5 months. Ten patients had anti-SCl-70, none had anticentromere, and two had antipolymerase. Tocilizumab treatment was provided as long as the patient's condition improved. Total treatment duration was 30.33 patient-years. Median treatment duration was 18.5 months, and 3 patients were treated for a period of 4 years and longer. Ten patients were treated with tocilizumab to the date of data collection. All were feeling good and maintained the achieved improvement throughout the treatment period. Improvement was recorded in 12 patients (75%). Mean reduction in modified Rodnan skin score was 11 points (p < 0.001), musculoskeletal and joint involvement improved in 75% and 80% of patients, respectively, and improvement in lung function was recorded in 46%. Patients with early SSc responded better to tocilizumab (p = 0.01). This is the largest reported case series of tocilizumab treatment in patients with SSc. The treatment was without significant side-effects and was beneficial for most patients, especially in early disease. The present study reinforces previous findings regarding the efficacy of tocilizumab in treating SSc.
DOI: 10.1016/j.berh.2019.01.011
PubMed: 31174825
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000370
- to stream PubMed, to step Curation: 000370
- to stream PubMed, to step Checkpoint: 000749
- to stream Ncbi, to step Merge: 002016
- to stream Ncbi, to step Curation: 002016
- to stream Ncbi, to step Checkpoint: 002016
- to stream Main, to step Merge: 001267
- to stream Main, to step Curation: 001268
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.</title><author><name sortKey="Zacay, Galia" sort="Zacay, Galia" uniqKey="Zacay G" first="Galia" last="Zacay">Galia Zacay</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine E, Meir Hospital, Kfar Saba, Israel; Sackler School of Medicine, University of Tel Aviv, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Medicine E, Meir Hospital, Kfar Saba, Israel; Sackler School of Medicine, University of Tel Aviv</wicri:regionArea><wicri:noRegion>University of Tel Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Levy, Yair" sort="Levy, Yair" uniqKey="Levy Y" first="Yair" last="Levy">Yair Levy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine E, Meir Hospital, Kfar Saba, Israel; Sackler School of Medicine, University of Tel Aviv, Israel. Electronic address: levy.yair@clalit.org.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Medicine E, Meir Hospital, Kfar Saba, Israel; Sackler School of Medicine, University of Tel Aviv</wicri:regionArea><wicri:noRegion>University of Tel Aviv</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:31174825</idno><idno type="pmid">31174825</idno><idno type="doi">10.1016/j.berh.2019.01.011</idno><idno type="wicri:Area/PubMed/Corpus">000370</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000370</idno><idno type="wicri:Area/PubMed/Curation">000370</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000370</idno><idno type="wicri:Area/PubMed/Checkpoint">000749</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000749</idno><idno type="wicri:Area/Ncbi/Merge">002016</idno><idno type="wicri:Area/Ncbi/Curation">002016</idno><idno type="wicri:Area/Ncbi/Checkpoint">002016</idno><idno type="wicri:Area/Main/Merge">001267</idno><idno type="wicri:Area/Main/Curation">001268</idno><idno type="wicri:Area/Main/Exploration">001268</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.</title><author><name sortKey="Zacay, Galia" sort="Zacay, Galia" uniqKey="Zacay G" first="Galia" last="Zacay">Galia Zacay</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine E, Meir Hospital, Kfar Saba, Israel; Sackler School of Medicine, University of Tel Aviv, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Medicine E, Meir Hospital, Kfar Saba, Israel; Sackler School of Medicine, University of Tel Aviv</wicri:regionArea><wicri:noRegion>University of Tel Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Levy, Yair" sort="Levy, Yair" uniqKey="Levy Y" first="Yair" last="Levy">Yair Levy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine E, Meir Hospital, Kfar Saba, Israel; Sackler School of Medicine, University of Tel Aviv, Israel. Electronic address: levy.yair@clalit.org.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Medicine E, Meir Hospital, Kfar Saba, Israel; Sackler School of Medicine, University of Tel Aviv</wicri:regionArea><wicri:noRegion>University of Tel Aviv</wicri:noRegion></affiliation></author></analytic><series><title level="j">Best practice & research. Clinical rheumatology</title><idno type="eISSN">1532-1770</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (pharmacology)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Scleroderma, Systemic (drug therapy)</term><term>Scleroderma, Systemic (pathology)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (pharmacologie)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sclérodermie systémique (anatomopathologie)</term><term>Sclérodermie systémique (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Sclérodermie systémique</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Scleroderma, Systemic</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Scleroderma, Systemic</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sclérodermie systémique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The treatment of systemic sclerosis (SSc) presents a clinical challenge because of the progressive nature of the disease, relatively poor prognosis, and lack of a proven treatment. In the last 10 years, several studies demonstrated the importance of interleukin 6 (IL6) as a pivotal cytokine in the development of fibrosis and angiopathy, especially in SSc. Tocilizumab, an IL6 receptor antibody, has shown promising results for patients with SSc. A total of 16 patients with SSc were treated with tocilizumab; 14 were female and 2 were male, with a median age of 45.5 years and median disease duration of 31.5 months. Ten patients had anti-SCl-70, none had anticentromere, and two had antipolymerase. Tocilizumab treatment was provided as long as the patient's condition improved. Total treatment duration was 30.33 patient-years. Median treatment duration was 18.5 months, and 3 patients were treated for a period of 4 years and longer. Ten patients were treated with tocilizumab to the date of data collection. All were feeling good and maintained the achieved improvement throughout the treatment period. Improvement was recorded in 12 patients (75%). Mean reduction in modified Rodnan skin score was 11 points (p < 0.001), musculoskeletal and joint involvement improved in 75% and 80% of patients, respectively, and improvement in lung function was recorded in 46%. Patients with early SSc responded better to tocilizumab (p = 0.01). This is the largest reported case series of tocilizumab treatment in patients with SSc. The treatment was without significant side-effects and was beneficial for most patients, especially in early disease. The present study reinforces previous findings regarding the efficacy of tocilizumab in treating SSc.</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Zacay, Galia" sort="Zacay, Galia" uniqKey="Zacay G" first="Galia" last="Zacay">Galia Zacay</name></noRegion><name sortKey="Levy, Yair" sort="Levy, Yair" uniqKey="Levy Y" first="Yair" last="Levy">Yair Levy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001268 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001268 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31174825
|texte= Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31174825" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |